ACHP

CAT: 0804-HY-107592Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-107592Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ACHP (compound 4j) is a selective and orally active IκB kinase inhibitor with IC50 values of 8.5 nM and 250 nM for IKKβ and IKKα, respectively. ACHP can effectively inhibit the STAT3 signaling pathway and induce cancer cell cycle arrest and apoptosis. ACHP shows anti-inflammatory activity in a mouse ear edema model. ACHP can be used in anti-inflammatory and anti-cancer (such as multiple myeloma and leukemia) studies[1][2][3][4].
CAS Number
[406208-42-2]
UNSPSC
12352005
Target
Apoptosis; IKK; STAT
Type
Reference compound
Related Pathways
Apoptosis; JAK/STAT Signaling; NF-κB; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/achp.html
Solubility
10 mM in DMSO
Smiles
NC1=NC(C(C(O)=CC=C2)=C2OCC3CC3)=CC(C4CCNCC4)=C1C#N
Molecular Formula
C21H24N4O2
Molecular Weight
364.44
References & Citations
[1]Sanda T, et al. Growth inhibition of multiple myeloma cells by a novel IkappaB kinase inhibitor. Clin Cancer Res. 2005 Mar 1;11 (5) :1974-82.|[2]Lee JH, et al. The IκB Kinase Inhibitor ACHP Targets the STAT3 Signaling Pathway in Human Non-Small Cell Lung Carcinoma Cells. Biomolecules. 2019 Dec 13;9 (12) :875.|[3]Sanda T, et al. Induction of cell death in adult T-cell leukemia cells by a novel IkappaB kinase inhibitor. Leukemia. 2006 Apr;20 (4) :590-8.|[4]Murata T, et al. Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: Orally active anti-inflammatory agents. Bioorg Med Chem Lett. 2004 Aug 2;14 (15) :4019-22.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IKK-α; IKK-β

Popular Products